Table 3.
24 Week change of neuropsychological tests, NPZ-8, and GDS by treatment, Intention to Treat (N=45)
| No Paroxetine arms mean (SD) | Paroxetine arms mean (SD) | p value | No Fluconazole arms mean (SD) | Fluconazole arms mean (SD) | p value | |
|---|---|---|---|---|---|---|
| N=19 | N=21 | N=20 | N=20 | |||
| CalCAP Choice Reaction time change * | −0.98 (1.54) | 0.55 (2.28) | 0.092 | −0.09 (2.60) | −0.12 (1.42) | 0.756 |
| CalCAP Sequential Reaction time change * | −0.23 (0.78) | 0.34 (1.22) | 0.014 | 0.03 (1.28) | 0.16 (0.82) | 0.968 |
| Symbol Digit change | −0.01 (0.94) | 0.28 (0.87) | 0.587 | −0.06 (0.78) | 0.35 (0.99) | 0.243 |
| Trail Making Part A change | 0.08 (0.90) | 0.02 (0.81) | 0.681 | 0.05 (0.81) | 0.05 (0.90) | 0.910 |
| Trail Making Part B change | −0.33 (0.90) | 0.49 (0.98) | 0.041 | 0.27 (0.91) | −0.06 (1.11) | 0.097 |
| Timed Gait change ** | −0.28 (1.10) | −0.19 (1.04) | 0.919 | 0.07 (1.00) | −0.51 (1.05) | 0.083 |
| Grooved Pegboard Dominant change *** | 0.02 (0.95) | 0.39 (0.97) | 0.241 | 0.28 (0.99) | 0.15 (0.97) | 0.438 |
| Grooved Pegboard non-dominant change *** | −0.02 (0.71) | 0.01 (0.98) | 0.163 | 0.13 (0.83) | −0.14 (0.89) | 0.351 |
| Hopkins Auditory Verbal Learning test Total change | 0.01 (0.98) | 0.12 (0.91) | 0.590 | −0.07 (0.85) | 0.21 (1.01) | 0.475 |
| Hopkins Auditory Verbal Learning test Delayed change | 0.43 (1.29) | −0.02 (1.30) | 0.554 | 0.18 (1.36) | 0.21 (1.27) | 0.987 |
| Rey Complex Figure Copy Change | −0.45 (1.62) | 0.18 (0.97) | 0.277 | −0.04 (1.47) | −0.20 (1.23) | 0.284 |
| Rey Complex Figure Delayed change | 0.02 (0.43) | 0.34 (0.58) | 0.085 | 0.28 (0.56) | 0.10 (0.50) | 0.178 |
| Stroop Color Interference change **** | −0.05 (0.87) | −0.04 (1.32) | 0.673 | −0.16 (1.30) | 0.08 (0.88) | 0.540 |
| Letter number sequencing change | 0.26 (0.72) | −0.40 (0.74) | 0.023 | −0.11 (0.92) | −0.07 (0.55) | 0.695 |
| FAS verbal fluency change | 0.02 (0.43) | 0.25 (0.53) | 0.020 | 0.28 (0.46) | −0.01 (0.50) | 0.018 |
| CES-D | −1.95 (10.79) | 1.09 (4.99) | 0.319 | −0.71 (6.34) | 0.10 (10.01) | 0.136 |
| NPZ-8 | −0.19 (0.46) | 0.25 (0.60) | 0.049 | 0.09 (0.65) | −0.01 (0.50) | 0.476 |
| GDS***** | 0.03 (0.35) | −0.07 (0.60) | 0.536 | 0.02 (0.34) | −0.07 (0.32) | 0.515 |
Models adjusted for baseline value, gender, treatment effect on CES-D depression (with the exception of the model for changes in CES-D), and plasma HIV RNA undetectable
*
Sample size (n) for this test: no paroxetine n=15, paroxetine n=20, no fluconazole n=19, fluconazole n=16
**
Sample size (n) for this test: no paroxetine n=15, paroxetine n=18, no fluconazole n=16, fluconazole n=17
***
Sample size (n) for this test: no paroxetine n=18, paroxetine n=21, no fluconazole n=20, fluconazole n=19
****
Sample size (n) for this test: no paroxetine n=18, paroxetine n=19, no fluconazole n=19, fluconazole n=18
*****
Higher numbers indicate worsening performance only for the GDS